Cargando…
A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
OBJECTIVES: American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116799/ https://www.ncbi.nlm.nih.gov/pubmed/30044320 http://dx.doi.org/10.1097/IGC.0000000000001305 |
_version_ | 1783351656556003328 |
---|---|
author | Murofushi, Keiko Nemoto Kitamura, Nozomi Yoshioka, Yasuo Sumi, Minako Ishikawa, Hitoshi Oguchi, Masahiko Sakurai, Hideyuki |
author_facet | Murofushi, Keiko Nemoto Kitamura, Nozomi Yoshioka, Yasuo Sumi, Minako Ishikawa, Hitoshi Oguchi, Masahiko Sakurai, Hideyuki |
author_sort | Murofushi, Keiko Nemoto |
collection | PubMed |
description | OBJECTIVES: American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up results. METHODS/MATERIALS: The study included 7 patients with vaginal cancer and 14 patients with cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5 mm or less or IBT for vaginal tumors less than 5 mm. Nine patients received ICT and the remaining 12 patients received IBT. For dosimetric comparison, an experimental recalculation as the virtual IBT for patients actually treated by ICT, and vice versa, was performed. RESULTS: The 5-year local control rate for all tumors was 89.4%. No differences in local control between ICT- and IBT-treated groups were observed (P = 0.21). One patient experienced a grade 3 rectal complication. There were no significant differences in the CTV D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the dosimetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT plans exceeded the limited dose for organs at risk, which were recommended in the guideline published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the experimental ICT plans was significantly higher than for the actual IBT plans (P < 0.001 and <0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for bladder and/or rectum D2cc. CONCLUSIONS: Tumor control and toxicity after selected brachytherapy according to vaginal tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc. |
format | Online Article Text |
id | pubmed-6116799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-61167992018-09-13 A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer Murofushi, Keiko Nemoto Kitamura, Nozomi Yoshioka, Yasuo Sumi, Minako Ishikawa, Hitoshi Oguchi, Masahiko Sakurai, Hideyuki Int J Gynecol Cancer Radiation Therapy OBJECTIVES: American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up results. METHODS/MATERIALS: The study included 7 patients with vaginal cancer and 14 patients with cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5 mm or less or IBT for vaginal tumors less than 5 mm. Nine patients received ICT and the remaining 12 patients received IBT. For dosimetric comparison, an experimental recalculation as the virtual IBT for patients actually treated by ICT, and vice versa, was performed. RESULTS: The 5-year local control rate for all tumors was 89.4%. No differences in local control between ICT- and IBT-treated groups were observed (P = 0.21). One patient experienced a grade 3 rectal complication. There were no significant differences in the CTV D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the dosimetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT plans exceeded the limited dose for organs at risk, which were recommended in the guideline published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the experimental ICT plans was significantly higher than for the actual IBT plans (P < 0.001 and <0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for bladder and/or rectum D2cc. CONCLUSIONS: Tumor control and toxicity after selected brachytherapy according to vaginal tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc. Lippincott Williams & Wilkins 2018-09 2018-07-23 /pmc/articles/PMC6116799/ /pubmed/30044320 http://dx.doi.org/10.1097/IGC.0000000000001305 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of IGCS and ESGO. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Radiation Therapy Murofushi, Keiko Nemoto Kitamura, Nozomi Yoshioka, Yasuo Sumi, Minako Ishikawa, Hitoshi Oguchi, Masahiko Sakurai, Hideyuki A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer |
title | A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer |
title_full | A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer |
title_fullStr | A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer |
title_full_unstemmed | A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer |
title_short | A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer |
title_sort | clinical evaluation of american brachytherapy society consensus guideline for bulky vaginal mass in gynecological cancer |
topic | Radiation Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116799/ https://www.ncbi.nlm.nih.gov/pubmed/30044320 http://dx.doi.org/10.1097/IGC.0000000000001305 |
work_keys_str_mv | AT murofushikeikonemoto aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT kitamuranozomi aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT yoshiokayasuo aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT sumiminako aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT ishikawahitoshi aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT oguchimasahiko aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT sakuraihideyuki aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT murofushikeikonemoto clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT kitamuranozomi clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT yoshiokayasuo clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT sumiminako clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT ishikawahitoshi clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT oguchimasahiko clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer AT sakuraihideyuki clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer |